Title: Metabolites and lipoproteins may predict the severity of early Acute Pancreatitis in a South African cohort.

3

Jeanet Mazibuko^{1†}, Nnenna Elebo^{1,2†}, Aurelia A. Williams³, Jones Omoshoro-Jones^{1,4}, John W. Devar^{1,4}, Martin Smith^{1,4}, Stefano Cacciatore², and Pascaline N. Fru^{1*}.

- ¹Department of Surgery, School of Clinical Medicine, Faculty of Health Sciences, University
 of the Witwatersrand, Johannesburg 2193, South Africa
- 8 ²Bioinformatics Unit, International Centre for Genetic Engineering and Biotechnology, Cape
- 9 Town 7925, South Africa
- 10
- 11 ³Centre for Human Metabolomics, Faculty of Natural and Agricultural Sciences, North-
- 12 West University, Potchefstroom 2531, South Africa
- 13 ⁴Hepatopancreatobiliary Unit, Department of Surgery, Chris Hani Baragwanath Academic
- 14 Hospital, Johannesburg 1864, South Africa
- 15
- 16 ***Corresponding author:**
- 17 Email: <u>pascaline.fru@wits.ac.za</u>, Tel: +27 (0) 11 7172476
- 18
- 19 [†] The authors contributed equally to this manuscript.

20 Abstract

21

Background: Acute pancreatitis (AP) is a common clinical disease with varying severity. The Revised Atlanta Classification (RAC) categorises AP into mild, moderately severe, and severe (MAP, MSAP and SAP) respectively. Despite the availability of different scoring systems to triage patients, these are not always suitable for predicting the course and outcome of certain patients during admission. In this study, untargeted metabolomics was used to identify metabolic parameters that can potentially be used as prognostic markers for stratifying the risk profiles of patients for improved management and treatment.

Methods: Serum isolated from blood samples collected from 30 AP patients (8 MAP, 14 MSAP, and 8 SAP) and 9 healthy control (HC) individuals was analysed using ¹H nuclear magnetic resonance (NMR) spectroscopy. Wilcoxon and Kruskal–Walli's rank-sum tests were used to compare differences in numerical covariates. A liposcale test was used for lipoprotein characterization and the Spearman rank test was conducted for correlation of the data. P-values < 0.05 were considered significant.</p>

- 35 Results: Elevated levels of lactate, (rho = 0.67; p-value < 0.001, FDR = 0.001), 3-
- 36 hydroxybutyrate (rho = 0.46; p-value < 0.003, FDR = 0.013), acetoacetate (rho = 0.63; p-value
- 37 < 0.001, FDR < 0.001) and lipid alpha-CH2 (rho = 0.45; p-value = 0.004, FDR = 0.013) were
- associated with AP severity as was decreased levels of ascorbate (rho = 0.46; p-value < 0.003,
- 39 FDR = 0.013), methanol (rho = 0.46; p-value < 0.003, FDR = 0.013), glutamine (rho = -0.55; p-
- 40 value < 0.001, FDR = 0.002), ethanol (rho = 0.64; p-value < 0.001, FDR < 0.001), protein-NH
- 41 (rho= -0.75; p-value < 0.001, FDR<0.001) among others. HDL-C decreased while IDL-C and
- 42 VLDL-C increased across all the AP metabolic phenotypes compared to the HC.

43 Conclusion: Dysregulated metabolites and lipids can potentially add to the understanding of
44 the pathophysiological conditions of AP and can aid in the early prognosis and stratification of
45 patients for specialist care.

46 Keywords: Acute pancreatitis; Metabolites; Lipoproteins; Severity; Nuclear Magnetic
47 Resonance

48 1) Introduction

49 Acute Pancreatitis (AP) is an inflammatory condition resulting from the autodigestion of the 50 pancreas caused by the sudden release of digestive enzymes before they reach the small 51 intestine. AP clinically presents with nausea, vomiting, abdominal pain, and an increase in 52 amylase and/or lipase in the blood of patients, which is at least three times greater than the 53 normal range (Hofmeyr et al., 2014; Nadhem and Salh, 2017). Globally, the incidence of AP 54 ranges from 5 and 80 people per 100,000 population (Nesvaderani et al., 2015). The incidence 55 of AP in the Western world is well documented, except for Asia and Latin America (Iannuzzi 56 et al., 2022), and low- and middle-income countries such as South Africa, which have a 57 paucity of information (Anderson et al., 2008). Discovery studies from our setting have shown 58 changes in immunological molecules or lack thereof in various stages of the disease (Kay et 59 al., 2017; Thomson et al., 2018, 2019; Nalisa et al., 2021), but incidence studies are still 60 lacking. While there is currently no incidence study of AP in South Africa, hospital prevalence 61 studies have shown that there are increasing hospital admissions due to AP (Funnell et al., 62 1993; John et al., 1997; Anderson et al., 2008). The most common aetiologies of AP worldwide 63 are biliary and alcohol induced (Zilio et al., 2019). Previously, alcohol-induced AP accounted 64 for most hospital admissions for pancreatitis while antiretroviral drugs (ARVs), endoscopic 65 retrograde cholangiopancreatography (ERCP), hypertriglyceridemia (HTG), or unknown 66 causes together contributed to 5% of the causes of this disease in South Africa (John et al., 67 1997; Anderson et al., 2008). In 2021, Nalisa and colleagues demonstrated a changing 68 demography of AP aetiology with increasing biliary-related disease which was proportional 69 with alcohol-induced AP (Nalisa et al., 2021). Risk factors such as obesity, age, genetic 70 predisposition, and alcohol abuse differ according to the lifestyle of the population (Yadav and 71 Lowenfels, 2013; Nesvaderani et al., 2015) and play a big role in these changes. In China for 72 example, AP caused by HTG has surpassed alcohol-induced AP due to dietary habits (Yang and 73 McNabb-Baltar, 2020) and it will not be surprising if similar trends are reported in African 74 populations as more Western dietary habits are adopted. Black males have been reported to 75 have a very high risk of AP attributed to social factors such as excessive alcohol consumption 76 (Yang, 2008).

77

According to the Revised Atlanta Classification (RAC) of 2021, AP is categorized into three classes namely mild AP (MAP), moderately severe AP (MSAP) and severe AP (SAP) (Banks et al., 2013; Choi et al., 2017). The most common form is MAP, which is a self-limiting disease, resolves within the first week or with minimum adverse effect. Moderately severe AP is characterized by organ failure that is transient and resolves within 48 hours (Banks et al., 2013). MSAP patients may develop local complications such as walled-off necrosis,

84 pseudocysts, pancreatic and peripancreatic necrosis, and pancreatic fluid collections (Afghani, 85 2014). Patients are diagnosed with SAP if organ failure persists for more than 48 hours after 86 admission and/or associated with pancreatic necrosis (Szatmary et al., 2022). Patients with AP 87 are at an increased risk of systemic inflammatory response syndrome (SIRS), due to the 88 activation of the immune system leading to complications such as organ failure and death 89 (Bruen et al., 2021). These patients present with local complications which persist due to the 90 compromised immune system and the resulting immune cascade increases the risk of mortality 91 by 30% (Banks et al., 2013; Yadav and Lowenfels, 2013). Therefore, the severity of the 92 inflammatory response in AP determines which patients will suffer organ failure and thus are 93 classified as severe cases or have a short self-limiting uncomplicated course, classified as 94 MAP.

95 AP has diverse presentations with clinical variations and an unpredictable course which makes 96 diagnosis and hence prognosis difficult due to changes in the threshold of blood enzymes such as 97 amylase and lipase (Treacy et al., 2001). The varying degrees of severity make it necessary for 98 patients to be evaluated on time in the emergency area for signs and symptoms which will aid in 99 the prevention of organ failure and/or death in patients during hospitalization. This is suggestive 100 of a tight therapeutic window, requiring swift responses, which involves monitoring, 101 intervention and supportive care which is ideally administered within the first 48-72 h from 102 disease onset (Gomatos et al., 2014). Although several rapid, cheap, and reliable tools have 103 been designed to assist clinicians to triage AP patients, sensitivity and specificity challenges 104 associated with the threshold change challenges with blood enzymes means prediction of the 105 disease severity and progression has not been easy and quick enough (Treacy et al., 2001; 106 Magrini et al., 2014; Gu and Tong, 2019; Silva-Vaz et al., 2020). Furthermore, the use of 107 computed tomography (CT) scan may be necessary in cases with diagnostic dilemma and/or 108 where determining the degree of necrosis, which is best demonstrable with imaging obtained 109 after 72 hours from the onset of AP is required (Leppäniemi et al., 2019). The use of these 110 techniques for the diagnosis of critically ill AP patients might delay treatment, which may result 111 in single or multiple organ failure and death, hence the need for more reliable and fast 112 alternatives.

113 Although, no effective medication exists for the treatment of AP, supportive care which is

dependent on the severity is applied (Banks et al., 2006). MSAP and SAP patients who require

specialized care are transferred to the intensive care unit (ICU). Antibiotics are administered to

116 patients with infected necrosis (Goodchild et al., 2019). In biliary-associated pancreatitis,

117 surgical interventions such as ERCP with early sphincterotomy can decrease the length of

118 hospital stay and complications (Quinlan, 2014; Chandrasekhara et al., 2017).

4

119 The initiation of AP causes alterations in biological processes due to the immune system being 120 activated in response to pancreatic injury (Zheng et al., 2013; Thomson et al., 2018; Nalisa et 121 al., 2021). The activated immune system affects metabolic processes by altering the blood 122 concentration of small molecules such as sugars, lipids, and amino acids (Gu and Tong, 2019; 123 Cacciatore et al., 2021; Elebo et al., 2021). The pancreas secretes digestive enzymes and 124 hormones, which play a key role in the regulation of metabolism, hence damage of pancreatic 125 cells as a result of AP affects the metabolome (Gu and Tong, 2019; Karpińska and Czauderna, 126 2022). This suggests that metabolomics of biofluids such as plasma and serum may be profiled to 127 retrieve information on the "health" status of the pancreas and pancreas-related diseases aiding in 128 the early detection, diagnosis and identification of novel biomarkers in pancreatic diseases (Gu 129 and Tong, 2019; Siddiqui et al., 2020). The earliest studies on the use of metabolomics to 130 determine metabolites in pancreatitis was the study by Bohus and colleagues and subsequently 131 various other studies have been conducted using different analytical techniques (Bohus et al.,

132 2008; Khan et al., 2013; Xu et al., 2016; Huang et al., 2019, 2022).

Nuclear magnetic resonance (NMR) spectroscopy is a technique used in metabolomics to 133 134 quantify a wide range of components, including low-molecular-weight metabolites, lipids, and lipoproteins (Sakai et al., 2012; Cacciatore and Loda, 2015; Silva et al., 2020; Elebo et al., 135 2021). The ¹H-NMR spectra allows resonances to be assigned directly to the metabolites based 136 137 on their chemical shifts, and signal multiplicities (Lindon and Nicholson, 2008). Several NMR 138 studies have shown that the integration of metabolites with meta-analysis of the transcriptome 139 revealed a pancreatitis background in pancreatic cancer, congruent with AP being a risk factor to pancreatic cancer (Ketavarapu et al., 2022). Furthermore, ¹H-NMR metabolomics has been 140 141 used to distinguish between AP patients and healthy controls or those presenting with 142 abdominal pain (Lusczek et al., 2013; Villaseñor et al., 2014; Shah et al., 2023). In the study by 143 Villaseñor and colleagues in 2014, the authors found changes in the lipid profile with high 144 levels of low-density lipoprotein and unsaturated lipids, which are consistent with known 145 disruptions in lipid metabolism in AP. Most of these studies were carried out in other races and 146 population groups using urine and plasma samples and although the studies targeted metabolites 147 in AP, they did not associate them with severity and outcome. It is also notable that genetic and 148 environmental variations in immune and metabolic responses based on ethnicity means such 149 studies are important in our patient cohort(Yadav and Lowenfels, 2013; Nesvaderani et al., 150 2015). Here, the serum metabolome of AP patients was profiled for the first time in an African cohort using ¹H-NMR spectroscopy. This study aimed to investigate altered metabolites and 151 152 lipids to understand the underlying pathophysiological conditions of AP in the three AP 153 severities to enable improved prognosis, for early patient stratification and management.

5

154

156

155 2 Materials and methods

157 **2.1 Sample collection and processing**

158 Ethics clearance for this study was obtained from the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (Ethics No. M190407). The RAC of 2012 159 (MAP, MSAP, or SAP) was used by consulting clinicians to recruit participants at the Chris 160 161 Hani Baragwanath Academic Hospital (CHBAH). To be included in the study, participants had 162 to be 18 or more years old and self-identified as of African descent. Patients were excluded if 163 they had been diagnosed with auto-immune diseases, undergoing immunotherapy, and were on 164 antibiotics within one month of admission. Following informed consent from the participants, 165 blood samples were collected using red coloured non-anticoagulant BD vacutainer® blood 166 collection tubes (BD Biosciences, New Jersey, USA). Four millilitres (4mL) of blood was 167 drawn from eligible patients as previously described by Nalisa and colleagues on days 1, 3, 5, 168 and 7 post epigastric pain enabling time points and longitudinal analysis of the metabolic 169 changes (Nalisa et al., 2021). Patients typically reported to hospital on Day 3 of pain.

170

171 The clinical data were obtained from the patient's hospital files, via the National Health 172 Laboratory Services (NHLS) Trakcare Web Results, version L6.10, captured on the RedCap® 173 (Tennessee, USA) database. Captured data included demographic, body mass index (BMI), AP aetiology, AP severity, clinical test results, and comorbidities. Healthy volunteers were 174 175 recruited as controls and were age and sex-matched with the AP patients. The collected blood 176 samples were allowed to stand upright for 30 minutes at room temperature in blood collection 177 tubes and then centrifuged at 1734 xg at 4°C for 30 minutes. The serum was aliquoted into 178 microfuge tubes of 500 μ L volumes and stored at -80°C until needed for the analysis.

179 2.2 Serum sample preparation

180 The frozen serum samples, previously processed and stored at -80° C were left to thaw at room 181 temperature. A working solution was prepared by adding 300 μ L of the thawed serum to 300 μ L 182 of a solution consisting of 0.75 M potassium phosphate buffer (pH 7.4), 5.81 mM of 183 trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP; Sigma-Aldrich, St. Louis, MO, USA) 184 and a trace amount of sodium azide (65 mg dissolved in deuterium oxide) to prevent bacterial 185 growth. The samples were vortexed to obtain a homogenous mixture. A final volume of 540 186 µL of each sample was transferred to a 5 mm NMR tube (Wilmad Lab Glass, Vineland, NJ, 187 USA) for analysis.

188 **2.3 Lipid Extract Preparation**

189 The extraction of the lipids was performed using the protocol described by Lamiquiz-Moneo

190 and colleagues (Lamiquiz-Moneo et al., 2019). A volume of 300 μ L of BUME (butanol: 191 methanol—2:1) was added to 100 μ L serum aliquots in glass GC vials as well as 300 μ L DIPE 192 (diisopropyl ether: ethyl acetate—3:1) and 300 μ L H \square O. Firstly, BUME and H \square O were added 193 to the samples and vortexed for 1 minute. DIPE was then added to extract the lipids and the 194 mixture incubated on a shaker for 10 minutes. To separate the lipids from the mixture, the 195 samples were centrifuged at 2058 xg for 5 minutes. Afterwards, the top layer was transferred 196 to clean vials, dried under liquid nitrogen at 37 °C and then resuspended in 600 µL solution of 197 CDCl3:CD3OD:D O (chloroform-d:methanol-d:water-d; 16:7:1, v/v/v) containing 1.18 mM 198 TSP. A volume of 540 µL of lipid extract samples were transferred to 5 mm NMR tubes 199 (Wilmad Lab Glass) and analysed using NMR spectroscopy.

200 2.4 NMR Analysis

201 The NMR tubes containing the diluted metabolite and lipid extracts, respectively were loaded 202 on a 500 MHz Bruker Avance III HD NMR spectrometer equipped with a triple- resonance 203 inverse 1H probe head and x,y,z gradient coils. Afterwards, one- dimensional (1D) proton 204 (1H)-NMR spectra were acquired using different pulse sequences. A standard nuclear 205 overhauser effect spectroscopy (NOESY) pulse sequence presat (noesygppr1d.comp) was used 206 on both the metabolite and lipid extract samples. NOESY was used to detect both signals of 207 small metabolites and high-molecular-weight macromolecules such as lipoproteins. 208 Additionally, a standard diffusion-edited (DIFF) pulse sequence (ledbpgppr2s1d) was used to 209 detect only high- molecular-weight macromolecules, such as lipoproteins. Pooled AP samples 210 of different severities were used as a quality control sample and were included in each batch 211 for qualitative assessment of repeatability by overlaying the raw spectra.

212 **2.5 NMR Profiling**

213

214 NMR spectroscopy was used to quantify a panel of 38 signals. The peaks of the identified 215 metabolites were fitted by combining a local baseline and Voigt functions based on the 216 multiplicity of the NMR signal (Marshall et al., 1997). The assignment of quantified signals is 217 reported in **Table S1**. To validate the efficacy of the different deconvolution models, the root-218 mean-square deviation was determined. The absolute concentration of each metabolite was 219 calculated according to a previously reported equation (Serkova et al., 2005). The number of 220 protons contributing to the unknown signals was imputed to 1. The concentration of 221 carbohydrates was also estimated by considering the equilibrium between their cyclic forms.

N-acetylglucosamine/galactosamine (GlycA) and N-acetylneuraminic acid (GlycB) signals
were quantified as inflammatory markers by integrating the areas between 2.00 and 2.05 ppm
and 2.09 and 2.05 ppm, respectively. GlycA is measured as an NMR signal of post-

225 translational modification of glycosylated acute-phase proteins released during inflammation 226 (Otvos et al., 2015). The Liposcale test (Biosfer TesLab, Reus, Spain) was then used to 227 determine lipoprotein parameters, high-density lipoprotein (HDL), low-density lipoprotein 228 (LDL), and very low-density lipoprotein (VLDL) particle number, size, and lipid concentration 229 of each subtype (Mallol et al., 2015), was used as previously described by (Elebo et al., 2021). 230 Each of the DIFF spectrum in the range between 0.1 and 9.5 ppm, excluding the regions 231 corresponding to the water signals between 4.40 and 5.00 ppm, was segmented into 0.001-ppm 232 chemical shift bins, and the corresponding spectral areas under the curve, giving a total of 8800 233 variables.

234 2.6 Statistics and Data Analysis235

Statistical analysis and graphical illustrations of the data were generated in R (version 3.6.1) and R studio (version 1.1.456) software using scripts developed in-house. Wilcoxon and Kruskal-Wallis rank-sum tests were used to compare differences in numerical covariates (e.g., age and metabolite concentration). Fisher's exact test was used to assess differences between categorical variables (e.g., gender), and Spearman's rank test was then used to calculate the correlation coefficient (rho) between variables. P-values < 0.05 were considered significant and to account for multiple testing, a false discovery rate (FDR) of <10% was applied.

The KODAMA algorithm, which allows for unsupervised extraction of features and enables analysis of noisy datasets of high dimension was used to facilitate the identification of patterns representing underlying metabolic phenotypes on all samples (Cacciatore et al., 2014, 2017; Bray et al., 2017). The partition around medoids (PAM) clustering (Reynolds et al., 2006) was applied to the KODAMA scores using the silhouette algorithm 10 (Rousseeuw, 1987) to verify the results obtained. The silhouette median value was utilized to assess the ideal number of clusters, ranging from 2 to 10.

Using partial least-squares (PLS) analysis, regression was performed on DIFF spectra metabolic profiles. Furthermore, 10-fold cross-validation was performed to evaluate the predictive efficacy of the model (Bertini et al., 2012). Both the goodness of fit parameter (R^2) and the predictive ability parameter (Q^2) were also calculated using standard formulas (Eriksson et al., 2003). The Q^2 value was calculated from the p-value to assess the performance of the PLS regression model (Szymańska et al., 2012). A p-value < 0.05 was regarded as significant.

256 3 Results

257

259

261

258 **3.1 Demographics and Clinical Characteristics**

260 3.1.1 Patients' demographic and clinicopathological characteristics

262 Thirty (30) patients with AP (MAP = 8, MSAP = 14, and SAP = 8) met the inclusion criteria

and 9 healthy controls (HC) were all enrolled in the study. There were equal number of males (11) and females (11). There were no statistically significant differences in BMI, age, and gender across the four groups as shown in **Table 1**. The primary aetiology of AP in this study was alcohol-induced (16/30 = 53%) occurring mostly in males (12/16=75%). Biliary associated-AP was the second common aetiology (12/30 = 40%) with majority being female (9/12=75%), and ARV-induced AP was 7% of the population (2/30) as shown in **Table S2**. In this study, 50% of AP patients with ARV-associated aetiology were women.

- 270 The incidence of organ dysfunction (OD) increased with the severity of AP, with 50% of
- 271 MSAP patients having respiratory OD as shown in **Table 1**. Imaging findings consistent with

local complications, such as pancreatic collection and wall-off necrosis, were found in some
MSAP and SAP patients. As expected, admissions to the Intensive Care Unit (ICU) and
hospital death were prevalent in SAP patients.

275

276 3.1.2 Routine clinical / Biochemical tests

277 No statistically significant correlation was observed between the severity of AP and routine 278 biochemical tests such as amylase, lipase, CRP, haemoglobin, haematocrit and platelets (Table 279 **S3**). The median values of liver function parameters; total bilirubin, conjugated bilirubin, 280 alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP) 281 were observed to be elevated above the physiological range for SAP patients. A third (10/30) of the patients in our cohort were affected by hypoalbuminemia, in contrast, no correlation with 282 283 severity was reported with CRP (Figure 1A). In this cohort, amylase and ALP (p < 0.001) showed statistically significantly higher concentrations in biliary-associated AP with their 284 285 combination able to differentiate biliary-associated from alcohol-associated AP as 286 demonstrated in Figure 1B.

\sim	<u>-</u>	-
~/>	× ,	1
~	וכ	
$\sim c$	٦c	2
11	57	5
~	~	

Table 1: Demographic and clinical characteristics of the acute pancreatitis patients

Feature	Control (n=9)	MAP (N=8)	MSAP (N=14)	SAP (N=8)	p-value
BMI (kg/m2), median [IQR]	30.4 [23.6	24.8 [24.7 44.3]	27 [23.2 30.5]	32 [30.9 39.8]	0.515
	32.8]				
Age (years), median [IQR]	43 [30 54]	43.5 [36.5 54.8]	38 [32 43.5]	48 [32.2 57.2]	0.613
Gender					0.100
F, n (%)	5 (55.6)	4 (50.0)	7 (50.0)	4 (50.0)	
M, n (%)	4 (44.4)	4 (50.0)	7 (50.0)	4 (50.0)	
Aetiology of pancreatitis					
Biliary, n (%)		4 (50.0)	5 (35.7)	3 (37.5)	
Alcohol, n (%)		4 (50.0)	8 (57.1)	4 (50.0)	
ARVs, n (%)		0 (0.0)	1 (7.1)	1 (12.5)	
Days of hospitalization, median [IQR]		10.5 [4.8 15]	9 [4.8 11]	8 [8 10]	0.864
no, n (%)		7 (87.5)	10 (71.4)	8 (100.0)	
yes, n (%)		1 (12.5)	4 (28.6)	0 (0.0)	
Diabetic					0.100
no, n (%)		8 (100.0)	13 (92.9)	8 (100.0)	
yes, n (%)		0 (0.0)	1 (7.1)	0 (0.0)	
HIV					0.650
no, n (%)		7 (87.5)	10 (71.4)	7 (87.5)	
yes, n (%)		1 (12.5)	4 (28.6)	1 (12.5)	
Organ dysfunction					0.027
no, n (%)		8 (100.0)	8 (57.1)	3 (37.5)	
renal, n (%)		0 (0.0)	0 (0.0)	1 (12.5)	
respiratory, n (%)		0 (0.0)	3 (21.4)	4 (50.0)	
transient renal, n (%)		0 (0.0)	3 (21.4)	0 (0.0)	
Local Complications					0.878
ANP, n (%)		1 (12.5)	0 (0.0)	0 (0.0)	
no, n (%)		7 (87.5)	10 (76.9)	6 (85.7)	
pancreatic collection, n (%)		0 (0.0)	1 (7.7)	0 (0.0)	
peripancreatic fatty stranding, n (%)		0 (0.0)	0 (0.0)	1 (14.3)	
wall off necrosis; ANC, n (%)		0 (0.0)	1 (7.7)	0 (0.0)	
yes, but not reported, n (%)		0 (0.0)	1 (7.7)	0 (0.0)	
Admission to ICU					0.004
no, n (%)		8 (100.0)	13 (92.9)	3 (37.5)	
ves, n (%)		0 (0.0)	1 (7.1)	5 (62.5)	
Surgical procedures					0.566
cholecystectomy, n (%)		2 (28.6)	1 (7.7)	0 (0.0)	
ERCP, n (%)		0 (0.0)	1 (7.7)	1 (14.3)	
None, n (%)		5 (71.4)	11 (6 (85.7)	
·			84.6)	< <i>></i>	
Hospital death			·		0.02
no, n (%)		8 (100.0)	13 (92.9)	4 (50.0)	
yes, n (%)		0 (0.0)	1 (7.1)	4 (50.0)	

289 290 291

Abbreviations, ARVs- antiretrovirals, HIV- human immunodeficiency virus, ANP- Atrial natriuretic peptide, ANC- absolute neutrophil count, ICU- intensive care unit, ERCP Endoscopic retrograde cholangiopancreatography, IQR- The Interquartile Range.

292 Most AP patients in this cohort showed a very high values of CRP (>10 mg/L). AP patients 293 with CRP higher than 150 mg/L and albumin lower than 35 g/L were more likely to experience 294 in-hospital death or have organ dysfunction (11/13=85%). A comparison of the biochemical 295 tests showed that both amylase (p-value <0.001; FDR= 0.008) and ALP (p-value <0.001; FDR= 296 0.003) were statistically different among the 3 different aetiologies of AP (Table S4). The 297 Glasgow Prognostic Score (GPS) reflects the systemic inflammatory response, derived from 298 the serum concentrations of CRP, and nutritional status, derived from the albumin levels 299 (Forrest et al., 2003). This score ranges from 0 to 2 with a higher value implying the presence 300 of both abnormalities high CRP and low albumin levels. Based on our reported CRP and 301 albumin levels, 32% (7/22) of AP patients had a GPS of 2, while 64% (14/22) AP patients had 302 a GPS score of 1 and 4% of patients had a GPS of 0. Furthermore, there were no statistically 303 significant differences observed for a comparative analysis between the different AP severity 304 groups and biochemical tests performed in biliary-associated AP (Table S5) and alcohol-305 associated AP (Table S6).



Figure 1. Plot showing (**A**) correlation between albumin and CRP: The top and middle right quadrants are patients with Glasgow Prognostic Score (GPS) =1 with CRP> 150mg/L and albumin levels > 35g/L while the left quadrants are patients with GPS =2. Although the top right quadrant has GPS=1, the patients are characterised with an elevated organ dysfunction levels and (**B**) the correlation between amylase and ALP: Decreased levels of both amylases and alkaline phosphatase (ALP) is associated with alcohol-associated AP while the increased levels are linked to biliary-associated AP. GPS of 0, 1 or 2 refers to neither, one or both abnormalities.

306 307

3.2 Metabolites and acute pancreatitis severity

NMR spectroscopy was used to profile the concentration of metabolites and lipids and in total 316 38 metabolic signals, including lipid classes and the NMR inflammatory markers, GlycA and 317 318 GlycB, were reported. To delineate the metabolic signatures of AP, the Spearman correlation 319 test was performed to link metabolic parameters to the different groups in the following rank order: HC=0, MAP =1, MSAP =2, and SAP = 3 (Table 2). Elevated levels of 3-320 321 hydroxybutyrate (3-HB), acetoacetate, phenylalanine, mannose, and lactate, as well as 322 decreased concentrations of ascorbate, methanol, ethanol, and glutamine was observed with 323 increased AP severity. Additionally, AP severity showed a large alteration in lipid profile with 324 increases lipid alpha-CH2 and decreases in cholesterol, Lipid=CH-CH2-CH=, Lipid beta-CH2 325 and lipid CH3 respectively with diseases severity as well as a depletion of the serum levels of 326 protein

327 (Protein NH). Furthermore, three unknown signals; 1.45, 1.11 and 1.06 ppm were observed to
328 be statistically significant. Although not statistically significant, inflammatory markers GlycA
329 and GlycB showed a positive correlation with the severity of the disease. The aetiology of AP,
330 i.e., alcohol or biliary-induced, did not have a significant impact on the metabolic profile

- 331 (Table S7).
- 332
- 333
- 334

Table 2 Correlation of concentrations of metabolites with the severity of acute pancreatitis

Feature	rho	p-value	FDR
Formate	0.04	0.793	0.809
Unknown signal at 8.12 ppm	0.01	0.951	0.951
Unknown signal at 8.07 ppm	-0.08	0.630	0.684
Phenylalanine	0.54	< 0.001	0.028
Tyrosine	-0.13	0.443	0.525
Unknown signal at 7.14 ppm	0.19	0.237	0.318
Histidine	-0.1	0.557	0.631
Glucose	0.24	0.140	0.238
Mannose	0.57	< 0.001	0.015
Unknown signal at 5.15 ppm	0.23	0.155	0.239
Unknown signal at 5.09 ppm	0.16	0.330	0.421
Unknown signal at 5.01 ppm	0.23	0.155	0.239
Ascorbate	-0.46	0.003	0.013
Threonine	-0.33	0.043	0.104
Lactate	0.67	<0.001	< 0.001
Creatinine	0.2	0.218	0.309
Creatine	0.3	0.064	0.143
Glycine	0.06	0.717	0.746
Methanol	-0.46	0.001	0.013
Unknown signal at 2.55 ppm	0.25	0.130	0.229
Citrate	-0.16	0.330	0.421
Glutamine	-0.55	<0.001	0.003
Pyruvate	0.2	0.230	0.317
Glutamate	0.25	0.126	0.229
Acetoacetate	0.63	<0.001	<0.001
Acetate	0.28	0.089	0.169
Alanine	-0.29	0.077	0.158
Unknown signal at 1.45 ppm	0.44	0.005	0.016
Unknown signal at 1.43 ppm	0.23	0.155	0.239
3-Hydroxybutyrate	0.46	<0.001	0.013
Ethanol	-0.64	<0.001	<0.001
Unknown signal at 1.16 ppm	-0.07	0.686	0.729
Unknown signal at 1.14 ppm	0.31	0.054	0.124
Unknown signal at 1.11 ppm	0.47	0.003	0.013
Unknown signal at 1.06 ppm	0.4	0.011	0.032
Valine	-0.14	0.411	0.511
Isoleucine	0.22	0.018	0.276
Leucine	0.11	0.049	0.564
2-Hydroxybutyrate	0.34	0.032	0.081
Protein NH	-0.75	< 0.001	< 0.001
Unsaturated lipid -CH=CH-	-0.35	0.029	0.077
Lipid alpha-CH2	0.45	0.004	0.013
Cholesterol	-0.43	0.006	0.017
Lipid =CH-CH2-CH=	-0.55	<0.001	0.002
Glycorol phospholipid	0.21	0.199	0.289
Phospholipid	-0.13	0.440	0.525
Lipid beta-CH2		<0.001	0.004
Lipid CH2	0.09	0.599	0.664
Lipid CH3	-0.44	0.005	0.016
GlycB	0.28	0.085	0.167
GlycA	0.29	0.074	0.158

Rho: Spearman's correlation coefficient; FDR: False Discovery rate

335 3.3 The Relationship between the metabolic phenotype and clinical outcomes of acute336 pancreatitis

337 Unsupervised KODAMA analysis was performed to visualize patterns between metabolic 338 phenotypes (metabotype) and disease severity as described in Figure 2A. This operation 339 separated the patient cohort into three different metabotypes. A distinct metabolic profile was 340 observed for the healthy controls compared to AP patients. Notably, a clear separation was 341 also evident between patients with MAP and SAP. Interestingly, two patients with SAP 342 showed a metabolic profile similar to the MAP. Further analysis indicated that these patients had elevated levels of free cholesterol/cholesterol ester ratio, which could be due to cholestasis 343 344 linked to lipoprotein X (LpX). Cholestasis is characterized by the presence of Lpx (Brandt et 345 al., 2015; Phatlhane and Zemlin, 2016), that could mask the SAP phenotype. The group of AP 346 patients with intermediate severity (i.e., MSAP) shared metabolic profiles with both MAP and 347 SAP patients (Figure 2B). However, MSAP patients with a closer phenotype to SAP had a 348 higher incidence of adverse events (Figure 2C). Some of the adverse events were complications 349 such as infection and pseudocysts, organ dysfunction (OD), and admission to the ICU. 350 Notably, increases in lactate activity, shown by the colour changes from blue through yellow 351 in the heatmap (Figure 2D), which is prevalent in the SAP patients also corresponds with 352 increase OD, local complications, ICU admission and death.

353 A further comparison of the clinical features and the metabolite profile showed that the lipid profile distinctively separated the metabolic phenotypes of AP based on their severity with an 354 355 overall decrease in lipid levels with increasing AP severity (Figure 2D). The concentration of 356 high-density lipoprotein particles (HDL-P) seemed to constitute the difference in the 357 dyslipidaemia found between the metabolic phenotypes, with a notable decrease with 358 increasing AP severity (Figure 2E). The inflammatory marker, GlycA, increased across the 359 group and was highest in the MSAP patients (Figure 2F). After further characterisation of 360 cholesterol-related lipids, it was shown that dysregulation of HDL (decreasing with severity) 361 and IDL and VLDL (both increasing with severity), were linked to AP severity (Figure 2G).







HDL- High-density lipoprotein, HDL-P- HDL-Particle, LDL- Low-density lipoprotein, VLDL-Very-Low Density Lipoprotein, IDL –
 immediate-density lipoprotein.

379 3.4 Trend Analysis

380 To further understand the association of metabolites and lipoproteins with AP severity, 381 KODAMA analysis was used to analyse three representative molecules (GlycA, 3-382 hydroxybutyrate and lipid alpha-CH2). A comparison of the metabolites (Table S8) and 383 lipoproteins (Table S9) with inverted first dimension KODAMA showed dysregulated 384 metabolites such as mannose, ascorbate, phenylalanine and lipoproteins among others as we move from MAP to SAP. Some of these metabolites were also dysregulated over time as days 385 progressed from days 1 - 7 for selected severities albeit inconsistently for example 3-386 387 hydroxybutyrate in SAP patients. The correlation of the concentration of metabolites with AP 388 severity showed that GlycA (p- value = 0.004) for example, was significantly altered (Figure 389 **3A**, **Table S10**). In this pilot study, the ketoacidosis metabolite, 3-hydroxybutyrate (p-value = 390 0.003) was shown to be significantly linked to worse clinical outcomes in AP as shown in 391 Figure **3B** (Table S11) and within the severe group this seems to increase with time from day1 392 to day 7. Elevated levels of 3-hydroxybutyrate were observed in SAP patients compared to the 393 other severity groups. A metabolite of interest, Lipid alpha-CH2 was observed to be 394 dysregulated in AP patients with organ dysfunction (Figure 3C). Elevated levels of alpha-CH2 395 (p-value = 0.007) were seen in SAP compared to MSAP and MAP (Table S12). Within 396 patients, it appeared to be consistent over time.



Figure 3: Trends in selected metabolic parameters. A; describes the pattern for GlycA in the severity groups of AP over all time points. B; assess levels of 3-hydroxybutyrate in the severity groups of AP over all time points. C; describes the pattern for lipid alpha-CH2 in the severity groups of AP over all time points.

405 4 Discussion

398

403 404

406

407 In this preliminary study, the demographics, clinicopathological characteristics, as well as the 408 metabolite and lipoprotein profiles of 30 AP patients were analysed to assess the relationship of 409 these parameters to AP severity and clinical outcome. Importantly, the identification of a 410 metabotype that could help in prognosticating AP disease severity was envisaged.

Approximately 57% (17/30) of the AP patients were obese with a BMI of 32 kg/m² and a median
IQR of 30.9 - 39.8 kg/m² in SAP. Notably, obesity was more common in patients with biliaryassociated AP. An increase in BMI of about 83% (10/12) was observed for the biliary-associated
AP. Previous studies have shown that comorbidities such as obesity affect the clinical outcomes of
AP (Khatua et al., 2017; Moran et al., 2018), and this is also true for the cohort evaluated.

Of interest, this study showed that alcohol-induced AP is the main aetiology of male AP patients while biliary associated AP is common in females. On the contrary, a retrospective study in a Western society showed biliary-induced AP, which is prevalent in females, to be the main cause of AP followed by alcohol, which was predominantly in males (Nesvaderani et al., 2015). Furthermore, over 50% of the female AP patients in this study were living with HIV/AIDS and on

antiretroviral therapy (ART). Acute pancreatitis is extremely high in people living with HIV/AIDS
(PLWHA), which could be due to the long-term use of antiretroviral therapy (ART) medications
such as corticosteroids and sulphonamides (Dragovic, 2013). Importantly, the aetiology of AP did
not have a notable impact on the metabolic profile as shown in Table S7, and this might be because
the course of the disease is not usually affected by the aetiology (Fonteh et al., 2018).

426 Serum amylase and lipase are routine tests used for the diagnosis of AP (Ismail and Bhayana, 427 2017). According to the South African NHLS report, the physiological concentrations of amylase 428 and lipase range from 28 -110 U/L and 13 - 60 U/L respectively (National Health Laboratory 429 Services 2019/20 Annual Report; National Health Amendment Bill: rejection | PMG, n.d.). Our 430 study participants had higher concentrations of both amylase and lipase, about three times above 431 the normal limit but no statistically significant differences were found between the groups 432 probably because of the small sample sizes. Elevated levels of amylases and ALP were observed 433 in our study population, which suggests liver damage or a blocked bile duct in biliary pancreatitis 434 (Fratantoni et al., 2021) hence these findings could be vital in distinguishing from alcohol-induced 435 AP (Hong et al., 2017). Indeed, this study confirms that the combination of amylase and ALP can 436 be used to differentiate biliary-associated AP from alcohol-associated AP (Güngör et al., 2011; 437 Thiyagarajan and Amirthavarshini Ponnuswamy, 2020).

438 This study further confirms the previously reported direct association of hypoalbuminemia with 439 severity and mortality in AP (Ocskay et al., 2021). Elevated inflammatory states have been shown 440 to decrease albumin levels via capillary leak or induction of shorter half-life associated with 441 increased severity (Soeters et al., 2019; Ocskay et al., 2021). In contrast, there was no correlation 442 reported between CRP and severity in AP in this cohort. This is not surprising given that there is 443 conflicting evidence in the literature on the role of CRP in discriminating complicated AP early in 444 the disease (Ahmad et al., 2021). Rather, CRP is considered useful in predicting severity when 445 used in combination with other scoring systems to differentiate mild from severe patients for early 446 decision making. Most AP patients in this cohort showed high values of CRP (>10 mg/L). Based on 447 these values, we further analysed the patients for systemic inflammation and nutritional status 448 using the GPS system. The data showed that 32% (7/22) of AP patients were classified with a GPS 449 of 2, 64% (14/22) with a GPS of 1; only 4% of patients were classified with a GPS of 0. From the 450 results, MSAP patients had the most complications and organ failure from pancreatic necrosis, 451 which ultimately results in organ failure if unresolved (Niknam et al., 2020). SAP had the most 452 number of deaths, which is unsurprising given that SAP is characterized by persistent organ failure 453 for over 48 hours (Foster et al., 2016). Most of these SAP patients also generally had higher CRP 454 levels and hypoalbuminemia. The disease progression leading to organ failure and/or death in AP

is usually due to SIRS, which is a response to an infection or an injury in the pancreas (Garg andSingh, 2019).

In this study, the physiological metabotype created was able to distinguish between the mild and the severe groups of patients. AP patients undergo a hypermetabolic condition, which dysregulates amino acid, lipid, and glucose metabolism (Kotan et al., 2023). Metabolites such as lactate, phenylalanine, mannose, and acetoacetate, and 3-HB increased in concentration while ascorbate, methanol, ethanol, and glutamine reduced with AP severity in this cohort. Similar findings have been reported by Li *et al.*, (2014) and Xiao *et al.*, (2017) in various AP settings (Li et al., 2014; Xiao et al., 2017).

Lactate levels were the most positively correlated metabolite with AP severity. Oxygen deficiency and increased energy consumption enhances anaerobic glycolysis, which occurs in the early phase of AP ultimately leading to elevated levels of lactate, a glycolytic metabolite (Li et al., 2014). Increased lactate concentration has been associated with persistent organ failure in AP (Valverde-López et al., 2017) and is independently associated with poor outcomes and death (McDonald et al., 2017). Increases in mannose levels also positively correlated with AP severity and are not surprising given the involvement of the glycolytic pathway (Xiao et al., 2017).

471 Organ failure and mortality have been associated with raised phenylalanine levels in the plasma of 472 AP patients (Chen et al., 2020; Xu et al., 2020). Increases in phenylalanine levels could be as result 473 of scavenging of tetrahydrobiopterin, a key co- factor involved in the conversion of phenylalanine to 474 tyrosine (Sandstrom et al., 2008). Dysregulated amino acid metabolism leads to the release of 475 excess acetyl CoA into the tricarboxylic acid (TCA) cycle, which is converted to ketone bodies 476 such as 3-HB (Li et al., 2014). Ketones, which are products of the oxidative pathway of alcohol 477 metabolites could be predictive of alcohol-induced AP (McGuire, 2006; Villaseñor et al., 2014). 478 Elevated levels of 3-HB in AP has been shown to differentiate between MAP and SAP (Xiao et al., 479 2017) and associated with poor survival rates in pancreatic cancer (Elebo et al., 2021). In this 480 study, the 3-HB increased with severity and was found to persist in the SAP patients over time 481 when a trend analysis was performed. Hydroxybutyrate dehydrogenase enzyme, which catalyses 482 the breakdown of 3-HB to acetoacetate, another ketone (Hoque et al., 2009), has been shown to 483 significantly increase with organ failure and SIRS (Xiao et al., 2020). The increasing levels of both 484 3-HB and acetoacetate with increasing severity is suggestive of the reversible reaction between the 485 two molecules with the possibility of an equilibrium. Hence, both 3-HB and acetoacetate could be 486 used as a clinical biomarker to predict worse outcomes.

487 It is not surprising that ascorbate (vitamin C) levels decreased in this study with increasing AP488 severity, a phenomenon that has been previously reported (Gao et al., 2021). Due to this deficiency

in ascorbate in AP, high doses of ascorbate have shown therapeutic efficacy in AP (Du et al.,
2003). Glutamine levels also significantly decreased with increasing AP severity. The consumption
of glutamine by immune cells is similar if not more than that of glucose and it is essential for
processes such as the proliferation of immune cells and the production of cytokines amongst others
(Cruzat et al., 2018). (The inflammatory and immune compromised patient, therefore, inevitably
experiences decreasing levels with severity as was the case here.

495

496 The level of two alcohols, methanol and ethanol, decreased with increasing AP severity but just like 497 the rest of the metabolites, were not significantly different between biliary and alcohol induced AP 498 patients (**Table S7**) as would have been expected. This lack of a strong metabolic signature is 499 supported by the fact that irrespective of the cause of AP, the trajectory is usually the same 500 (Fonteh et al., 2018), hence aetiology does not influence metabotype. In addition, the mechanisms 501 underlying the aetiology of AP have not been extensively elucidated especially for alcohol-502 induced AP and could potentially shed light on this. This study showed a dyslipidaemic profile 503 with AP groups distinctly based on their severity. Serum lipid levels are associated with the 504 severity of acute pancreatitis (Khan et al., 2013; Zhang et al., 2017). Small HDL-P decreased with 505 increased severity of AP. Studies have shown that small HDL-P played a vital role in the ATP 506 binding Cassette transporter A 1 (ABCA-1) mediated cholesterol efflux from macrophages, which 507 leads to the deployment of intracellular cholesterol to the plasma membrane (Du et al., 2015). 508 HDL-C decreased from HC to SAP while IDL and VLDL increased with severity. Recent studies 509 demonstrated that decreased HDL- C levels are an independent prognostic factor of adverse 510 outcomes such as persistent organ failure and death (Zhang et al., 2017). HDL-C possesses anti-511 inflammatory properties, hence decreased amounts could be latent for AP severity (Murphy and 512 Woollard, 2010). Oxidized VLDL is a marker of oxidative stress which inhibits lipoprotein lipase 513 responsible for triglyceride (TG) metabolism (Jong et al., 2000). Elevated VLDL levels are 514 associated with HTG which is the third leading cause of AP and correlates with increased severity 515 (Yang and McNabb-Baltar, 2020), raising the question whether there could be HTG associated AP 516 in the study setting. Protein concentration decreased with increased severity in this study 517 confirming that AP promotes protein catabolism, which involves the breakdown of proteins into 518 amino acids (Singh et al., 2012). Hence, the presence of pancreatic inflammation could lead to an 519 alteration in the level of metabolites (Xiao et al., 2017).

520 This study confirms that inflammation plays a vital role in AP severity (Iyer et al., 2020). AP patients 521 with CRP > 150 mg/L and Albumin < 35 g/L were more likely to die in- hospital or have organ 522 dysfunction. Furthermore, GlycA was most elevated in MSAP with a slight increase in the SAP 523 patients, suggesting increased inflammation levels in MSAP compared to MAP and SAP. Although

the differences in GlycA between the groups in this study were not significantly different, it is notable that in a recent study, Shah and colleagues show that GlycA could be used as a novel diagnostic marker of inflammation in AP when compared to healthy controls (Shah et al., 2023). Increases in GlycA and GlycB have been shown in other acute phase inflammatory diseases such as COVID-19 (Holmes et al., 2021; Lodge et al., 2021). Here, we show that GlycA could be targeted as a biomarkers of inflammation in AP.

530 The transcription factor, NF- $_kB$, has been shown to promote the expression of genes involved in 531 inflammation, which are vital in various AP stages (Rakonczay et al., 2008). AP is an immune 532 disorder characterized by the release of either anti or proinflammatory cytokines (Zhang et al., 533 2017). The impaired anti-inflammatory function might be linked to reduced HDL-C levels in AP 534 leading to increased free fatty acids (FFAs), which produce an acidic microenvironment (Zhang et 535 al., 2017). HDL-C also possesses an antioxidant ability, which is mediated by the paraoxonase-1 536 activity in AP (Yuksekdag et al., 2019). Notably, the presence of FFAs results from the breakdown 537 of TG including chylomicrons and is associated with HTG AP. The TGs are inherently not toxic but 538 the resultant lipotoxicity from the FFAs causes the release of intracellular calcium resulting in acinar 539 cell injury (Yang and McNabb-Baltar, 2020).

540 *Study limitations*

541 "Sick" control samples of patients presenting with other inflammatory diseases that could result in 542 the production of similar metabolites or lipoprotein profiles were not included in this study, hence 543 the specificity of the metabolic changes could not be fully ascertained. However, given that 544 metabolites in different diseases could be different due to differences in the disease course, 545 metabolomics testing stands to differentiate these markers due to the differing specificities and the 546 associated time bound nature (Gu and Tong, 2019). This study is a pilot study with small samples 547 sizes (30 AP patients), but comparatively, similar to other high profile published work and 548 findings.

549 Conclusion: This study provides crucial information for subsequent validation studies on a larger 550 cohort. These preliminary findings point to the possibility of using metabolites and lipoproteins in 551 delineating AP severity which adds value in understanding the pathophysiological conditions of 552 this disease, hence ultimately leading to early diagnosis and better care.

553

555

554 **Conflict of interest**

- The authors declare that the research was conducted in the absence of any commercial or financialrelationships that could be construed as a potential conflict of interest.
- 558

559 Author contributions

560 JM: Sample acquisition/processing, analysis, interpretation, writing-original draft, writing- review 561 and editing. NE: formal analysis, interpretation, writing-original draft, writing-review and editing. 562 AW: design/methodology, formal analysis, interpretation, writing-review and editing. OM: clinical 563 data acquisition, formal analysis, interpretation, writing-review and editing. JD: clinical data 564 acquisition, interpretation, writing-review and editing, MD: clinical data analysis, interpretation, 565 writing-review and editing. SC: contributed analytical tools, methodology data analysis, 566 interpretation, writing-review and editing. PF: conceptualisation, obtained funding, formal analysis 567 and interpretation, project administration, supervision, writing-review and editing. All authors 568 approved the final version.

569

570 Funding

This study was supported by the South African National Research Foundation Grant 121277 and
the University of the Witwatersrand Faculty Research Committee Individual Grant
001254844110151211055254.

574

575 Acknowledgements

576

577 The patients, clinical staff, and clerks at Chris Hani Baragwanath Academic Hospital, 578 Hepatopancreatobiliary Unit and the Department of Surgery of the University of the 579 Witwatersrand are acknowledged. The Human Metabolomics Centre at the North-West University 580 for NMR Spectroscopy studies.

581

583

582 Supplementary material

584 **Tables S1-S10** where **Table S1** is the table of quantified signals and their relative assignment and 585 multiplicity; **Table S2** is the Aetiology and clinical characteristics of the AP patients, **Table S3**: 586 Clinical tests of patients with acute pancreatitis of different severity groups; **Table S4**. Comparison 587 of biochemical tests for the different aetiologies of acute pancreatitis; Table S5. Clinical tests of 588 patients with acute pancreatitis with biliary aetiology. All values are represented as median; **Table** 589 **S6:** Clinical tests of patients with alcohol-induced AP, values are represented as median; **Table** 590 **S7:** Comparison of metabolites with different aetiology groups of Acute Pancreatitis; **Table S8:** 591 Correlation of metabolites with inverted first dimension of KODAMA. Significantly dysregulated 592 metabolites and lipids; Table S9: Spearman correlation between lipoprotein parameters and 593 inverted first dimension of KODAMA and Table S10: Comparison of Metabolites and lipids with 594 severity in Acute Pancreatitis.

595 Data availability statement

All data produced in the present study are available upon reasonable request to the authors.

597 598	References
599 600 601	Afghani, E. (2014). Introduction to Pancreatic Disease: Acute Pancreatitis. <i>Pancreapedia Exocrine</i> <i>Pancreas Knowl. Base.</i> doi: 10.3998/panc.2014.14.
602 603 604	Ahmad, R., Bhatti, K. M., Ahmed, M., Malik, K. A., Rehman, S., Abdulgader, A., et al. (2021). C- Reactive Protein as a Predictor of Complicated Acute Pancreatitis: Reality or a Myth? <i>Cureus</i> . doi: 10.7759/cureus.19265.
605 606 607	Anderson, F., Thomson, S. R., Clarke, D. L., and Loots, E. (2008). Acute pancreatitis : demographics, aetiological factors and outcomes in a regional hospital in South Africa : general surgery. S. Afr. J. Surg. 46, 83–86. doi: 10.10520/EJC66759.
608 609 610	Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., et al. (2013). Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. <i>Gut</i> 62, 102–111. doi: 10.1136/gutjnl-2012-302779.
611 612	Banks, P. A., Freeman, M. L., and Gastroenterology, P. P. C. of the A. C. of (2006). Practice Guidelines in Acute Pancreatitis. <i>Off. J. Am. Coll. Gastroenterol. ACG</i> 101, 2379.
613 614 615	Bertini, I., Cacciatore, S., Jensen, B. V., Schou, J. V., Johansen, J. S., Kruhøffer, M., et al. (2012). Metabolomic NMR Fingerprinting to Identify and Predict Survival of Patients with Metastatic Colorectal Cancer. <i>Cancer Res.</i> 72, 356–364. doi: 10.1158/0008-5472.CAN-11-1543.
616 617 618	Bohus, E., Coen, M., Keun, H. C., Ebbels, T. M. D., Beckonert, O., Lindon, J. C., et al. (2008). Temporal Metabonomic Modeling of I-Arginine-Induced Exocrine Pancreatitis. <i>J. Proteome</i> <i>Res.</i> 7, 4435–4445. doi: 10.1021/pr800407j.
619 620 621	Brandt, E. J., Regnier, S. M., Leung, E. K., Chou, S. H., Baron, B. W., Te, H. S., et al. (2015). Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis. <i>Clin. Lipidol.</i> 10, 305–312. doi: 10.2217/clp.15.23.
622 623 624	Bray, R., Cacciatore, S., Jimenez, B., Cartwright, R., Digesu, A., Fernando, R., et al. (2017). Urinary metabolic phenotyping of women with lower urinary tract symptoms. <i>4216</i> . doi: 10.1021/acs.jproteome.7b00568.
625 626 627 628	Bruen, C., Miller, J., Wilburn, J., Mackey, C., Bollen, T. L., Stauderman, K., et al. (2021). Auxora for the Treatment of Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome. <i>Pancreas</i> 50, 537–543. doi: 10.1097/MPA.00000000001793.
629 630	Cacciatore, S., and Loda, M. (2015). Innovation in metabolomics to improve personalized healthcare. <i>Ann. N. Y. Acad. Sci.</i> 1346, 57–62. doi: 10.1111/nyas.12775.
631 632	Cacciatore, S., Luchinat, C., and Tenori, L. (2014). Knowledge discovery by accuracy maximization. <i>Proc. Natl. Acad. Sci.</i> 111, 5117–5122. doi: 10.1073/pnas.1220873111.
633 634 635	Cacciatore, S., Tenori, L., Luchinat, C., Bennett, P. R., and MacIntyre, D. A. (2017). KODAMA: an R package for knowledge discovery and data mining. <i>Bioinformatics</i> 33, 621–623. doi: 10.1093/bioinformatics/btw705.
636 637 638	Cacciatore, S., Wium, M., Licari, C., Ajayi-Smith, A., Masieri, L., Anderson, C., et al. (2021). Inflammatory metabolic profile of South African patients with prostate cancer. <i>Cancer</i> <i>Metab.</i> 9, 29. doi: 10.1186/s40170-021-00265-6.
639 640	Chandrasekhara, V., Khashab, M. A., Muthusamy, V. R., Acosta, R. D., Agrawal, D., Bruining, D. H., et al. (2017). Adverse events associated with ERCP. <i>Gastrointest. Endosc.</i> 85, 32–47.

- 641 doi: 10.1016/j.gie.2016.06.051.
- 642 Chen, W.-S., Wang, C.-H., Cheng, C.-W., Liu, M.-H., Chu, C.-M., Wu, H.-P., et al. (2020). Elevated
 643 plasma phenylalanine predicts mortality in critical patients with heart failure. *ESC Heart*644 *Fail.* 7, 2884–2893. doi: 10.1002/ehf2.12896.
- Choi, J.-H., Kim, M.-H., Cho, D. H., Oh, D., Lee, H. W., Song, T. J., et al. (2017). Revised Atlanta
 classification and determinant-based classification: Which one better at stratifying
 outcomes of patients with acute pancreatitis? *Pancreatology* 17, 194–200. doi:
 10.1016/j.pan.2017.01.004.
- 649 Cruzat, V., Macedo Rogero, M., Noel Keane, K., Curi, R., and Newsholme, P. (2018). Glutamine:
 650 Metabolism and Immune Function, Supplementation and Clinical Translation. *Nutrients* 10, 651 1564. doi: 10.3390/nu10111564.
- Dragovic, G. (2013). Acute pancreatitis in HIV/AIDS patients: an issue of concern. Asian Pac. J.
 Trop. Biomed. 3, 422–425. doi: 10.1016/S2221-1691(13)60091-X.
- Du, W.-D., Yuan, Z.-R., Sun, J., Tang, J.-X., Cheng, A.-Q., Shen, D.-M., et al. (2003). Therapeutic
 efficacy of high-dose vitamin C on acute pancreatitis and its potential mechanisms. *World J. Gastroenterol.* 9, 2565–2569. doi: 10.3748/wjg.v9.i11.2565.
- Du, X.-M., Kim, M.-J., Hou, L., Le Goff, W., Chapman, M. J., Van Eck, M., et al. (2015). HDL
 Particle Size Is a Critical Determinant of ABCA1-Mediated Macrophage Cellular Cholesterol
 Export. *Circ. Res.* 116, 1133–1142. doi: 10.1161/CIRCRESAHA.116.305485.
- Elebo, N., Omoshoro-Jones, J., Fru, P. N., Devar, J., De Wet van Zyl, C., Vorster, B. C., et al.
 (2021). Serum Metabolomic and Lipoprotein Profiling of Pancreatic Ductal Adenocarcinoma Patients of African Ancestry. *Metabolites* 11, 663. doi: 10.3390/metabo11100663.
- Eriksson, L., Jaworska, J., Worth, A. P., Cronin, M. T. D., McDowell, R. M., and Gramatica, P.
 (2003). Methods for reliability and uncertainty assessment and for applicability evaluations
 of classification- and regression-based QSARs. *Environ. Health Perspect.* 111, 1361–1375.
 doi: 10.1289/ehp.5758.
- Fonteh, P., Smith, M., and Brand, M. (2018). Adaptive Immune Cell Dysregulation and Role in
 Acute Pancreatitis Disease Progression and Treatment. *Arch. Immunol. Ther. Exp.* (*Warsz.*) 66, 199–209. doi: 10.1007/s00005-017-0495-1.
- Forrest, L. M., McMillan, D. C., McArdle, C. S., Angerson, W. J., and Dunlop, D. J. (2003).
 Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. *Br. J. Cancer* 89, 1028–1030. doi: 10.1038/sj.bjc.6601242.
- Foster, B. R., Jensen, K. K., Bakis, G., Shaaban, A. M., and Coakley, F. V. (2016). Revised Atlanta
 Classification for Acute Pancreatitis: A Pictorial Essay. *RadioGraphics*. doi:
 10.1148/rg.2016150097.
- Fratantoni, M. E., Giuffrida, P., Di Menno, J., Ardiles, V., de Santibañes, M., Clariá, R. S., et al.
 (2021). Prevalence of Persistent Common Bile Duct Stones in Acute Biliary Pancreatitis
 Remains Stable Within the First Week of Symptoms. *J. Gastrointest. Surg.* 25, 3178–3187.
 doi: 10.1007/s11605-021-05068-0.
- Funnell, I. C., Bornman, P. C., Weakley, S. P., Terblanche, J., and Marks, I. N. (1993). Obesity: An
 important prognostic factor in acute pancreatitis. *BJS Br. J. Surg.* 80, 484–486. doi:
 10.1002/bjs.1800800426.
- Gao, L., Chong, E., Pendharkar, S., Phillips, A., Ke, L., Li, W., et al. (2021). The Challenges and

- 685 Effects of Ascorbic Acid Treatment of Acute Pancreatitis: A Systematic Review and Meta-
- 686 Analysis of Preclinical and Clinical Studies. *Front. Nutr.* 8. Available at:
- 687 https://www.frontiersin.org/articles/10.3389/fnut.2021.734558 [Accessed October 5, 2023].
- 688 Garg, P. K., and Singh, V. P. (2019). Organ Failure Due to Systemic Injury in Acute Pancreatitis. 689 *Gastroenterology* 156, 2008–2023. doi: 10.1053/j.gastro.2018.12.041.
- Gomatos, I. P., Xiaodong, X., Ghaneh, P., Halloran, C., Raraty, M., Lane, B., et al. (2014).
 Prognostic markers in acute pancreatitis. *Expert Rev. Mol. Diagn.* 14, 333–46. doi: 10.1586/14737159.2014.897608.
- Goodchild, G., Chouhan, M., and Johnson, G. J. (2019). Practical guide to the management of
 acute pancreatitis. *Frontline Gastroenterol.* 10, 292–299. doi: 10.1136/flgastro-2018101102.
- 696 Gu, W., and Tong, Z. (2019). Clinical Application of Metabolomics in Pancreatic Diseases: A Mini-697 Review. *Lab. Med.*, 116–121. doi: 10.1093/labmed/lmz046.
- Güngör, B., Çağlayan, K., Polat, C., Şeren, D., Erzurumlu, K., and Malazgirt, Z. (2011). The
 Predictivity of Serum Biochemical Markers in Acute Biliary Pancreatitis. *ISRN Gastroenterol.* 2011, 1–5. doi: 10.5402/2011/279607.
- Hofmeyr, S., Meyer, C., and Warren, B. L. (2014). Serum lipase should be the laboratory test of
 choice for suspected acute pancreatitis. S. Afr. J. Surg. 52, 72–75.
- Holmes, E., Wist, J., Masuda, R., Lodge, S., Nitschke, P., Kimhofer, T., et al. (2021). Incomplete
 Systemic Recovery and Metabolic Phenoreversion in Post-Acute-Phase Nonhospitalized
 COVID-19 Patients: Implications for Assessment of Post-Acute COVID-19 Syndrome. *J. Proteome Res.* 20, 3315–3329. doi: 10.1021/acs.jproteome.1c00224.
- Hong, W., Geng, W., Chen, B., Basharat, Z., Wu, Q., Zimmer, V., et al. (2017). Predictors of acute
 pancreatitis with low elevation of serum amylase. *Ther. Clin. Risk Manag.* 13, 1577–1584.
 doi: 10.2147/TCRM.S147594.
- Hoque, M. M., Shimizu, S., Juan, E. C. M., Sato, Y., Hossain, M. T., Yamamoto, T., et al. (2009).
 Structure of d-3-hydroxybutyrate dehydrogenase prepared in the presence of the substrate
 d-3-hydroxybutyrate and NAD+. *Acta Crystallograph. Sect. F Struct. Biol. Cryst. Commun.*65, 331–335. doi: 10.1107/S1744309109008537.
- Huang, J., He, D., Chen, L., Dong, C., Zhang, S., Qin, Y., et al. (2019). GC-MS based
 metabolomics strategy to distinguish three types of acute pancreatitis. *Pancreatology* 19, 630–637. doi: 10.1016/j.pan.2019.05.456.
- Huang, Y., Wen, Y., Wang, R., Hu, L., Yang, J., Yang, J., et al. (2022). Temporal metabolic
 trajectory analyzed by LC-MS/MS based targeted metabolomics in acute pancreatitis
 pathogenesis and Chaiqin Chengqi decoction therapy. *Phytomedicine* 99, 153996. doi:
 10.1016/j.phymed.2022.153996.
- Iannuzzi, J. P., King, J. A., Leong, J. H., Quan, J., Windsor, J. W., Tanyingoh, D., et al. (2022).
 Global Incidence of Acute Pancreatitis Is Increasing Over Time: A Systematic Review and Meta-Analysis. *Gastroenterology* 162, 122–134. doi: 10.1053/j.gastro.2021.09.043.
- Ismail, O. Z., and Bhayana, V. (2017). Lipase or amylase for the diagnosis of acute pancreatitis?
 Clin. Biochem. 50, 1275–1280. doi: 10.1016/j.clinbiochem.2017.07.003.
- Iyer, S., Bawa, E. P., Tarique, M., and Dudeja, V. (2020). Know Thy Enemy—Understanding the
 Role of Inflammation in Severe Acute Pancreatitis. *Gastroenterology* 158, 46–48. doi:
 10.1053/j.gastro.2019.11.039.

- John, K. D., Segal, I., Hassan, H., Levy, R. D., and Amin, M. (1997). Acute pancreatitis in sowetan africans. *Int. J. Pancreatol.* 21, 149–155. doi: 10.1007/BF02822386.
- Jong, M. C., Hendriks, W. L., van Vark, L. C., Dahlmans, V. E. H., Groener, J. E. M., and Havekes,
 L. M. (2000). Oxidized VLDL Induces Less Triglyceride Accumulation in J774 Macrophages
 Than Native VLDL Due to an Impaired Extracellular Lipolysis. *Arterioscler. Thromb. Vasc.*Biol. 20, 144–151. doi: 10.1161/01.ATV.20.1.144.
- Karpińska, M., and Czauderna, M. (2022). Pancreas—Its Functions, Disorders, and Physiological Impact on the Mammals' Organism. *Front. Physiol.* 13. Available at: https://www.frontiersin.org/articles/10.3389/fphys.2022.807632 [Accessed October 5, 2023].
- Kay, P. S., Smith, M., and Br, M. (2017). The Initiating Immune Response of Acute Pancreatitis
 May be Mediated by the T-Helper 17 Pathway. *J. Pancreas* 18, 0–0.
- Ketavarapu, V., Ravikanth, V., Sasikala, M., Rao, G. V., Devi, Ch. V., Sripadi, P., et al. (2022).
 Integration of metabolites from meta-analysis with transcriptome reveals enhanced SPHK1
 in PDAC with a background of pancreatitis. *BMC Cancer* 22, 792. doi: 10.1186/s12885022-09816-6.
- Khan, J., Nordback, I., and Sand, J. (2013). Serum Lipid Levels Are Associated with the Severity of
 Acute Pancreatitis. *Digestion* 87, 223–228. doi: 10.1159/000348438.
- Khatua, B., El-Kurdi, B., and Singh, V. P. (2017). Obesity and pancreatitis. *Curr. Opin. Gastroenterol.* 33, 374–382. doi: 10.1097/MOG.0000000000386.
- Kotan, R., Peto, K., Deak, A., Szentkereszty, Z., and Nemeth, N. (2023). Hemorheological and
 Microcirculatory Relations of Acute Pancreatitis. *Metabolites* 13, 4. doi:
 10.3390/metabo13010004.
- Lamiquiz-Moneo, Civeira, Gómez-Coronado, Blanco-Vaca, Villafuerte-Ledesma, Gil, et al. (2019).
 Lipid Profile Rather Than the LCAT Mutation Explains Renal Disease in Familial LCAT
 Deficiency. J. Clin. Med. 8, 1860. doi: 10.3390/jcm8111860.
- Leppäniemi, A., Tolonen, M., Tarasconi, A., Segovia-Lohse, H., Gamberini, E., Kirkpatrick, A. W.,
 et al. (2019). 2019 WSES guidelines for the management of severe acute pancreatitis. *World J. Emerg. Surg.* 14, 27. doi: 10.1186/s13017-019-0247-0.
- Li, J., Zhao, X., Liu, Y., Peng, X., Zhu, S., Guo, H., et al. (2014). 1HNMR-based metabolomic
 profile of rats with experimental acute pancreatitis. *BMC Gastroenterol.* 14, 115. doi:
 10.1186/1471-230X-14-115.
- Lindon, J. C., and Nicholson, J. K. (2008). Analytical technologies for metabonomics and
 metabolomics, and multi-omic information recovery. *TrAC Trends Anal. Chem.* 27, 194–
 204. doi: 10.1016/j.trac.2007.08.009.
- Lodge, S., Nitschke, P., Kimhofer, T., Wist, J., Bong, S.-H., Loo, R. L., et al. (2021). Diffusion and Relaxation Edited Proton NMR Spectroscopy of Plasma Reveals a High-Fidelity
 Supramolecular Biomarker Signature of SARS-CoV-2 Infection. *Anal. Chem.* 93, 3976– 3986. doi: 10.1021/acs.analchem.0c04952.
- Lusczek, E. R., Paulo, J. A., Saltzman, J. R., Kadiyala, V., Banks, P. A., Beilman, G., et al. (2013).
 Urinary 1H-NMR Metabolomics Can Distinguish Pancreatitis Patients from Healthy
 Controls. JOP J. Pancreas 14, 161–170.
- Magrini, L., Gagliano, G., Travaglino, F., Vetrone, F., Marino, R., Cardelli, P., et al. (2014).
 Comparison between white blood cell count, procalcitonin and C reactive protein as

- diagnostic and prognostic biomarkers of infection or sepsis in patients presenting to
 emergency department. *Clin. Chem. Lab. Med. CCLM* 52, 1465–1472. doi: 10.1515/cclm2014-0210.
- Mallol, R., Amigó, N., Rodríguez, M. A., Heras, M., Vinaixa, M., Plana, N., et al. (2015). Liposcale:
 a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy [S]. *J. Lipid Res.* 56, 737–746. doi: 10.1194/jlr.D050120.
- Marshall, I., Higinbotham, J., Bruce, S., and Freise, A. (1997). Use of voigt lineshape for
 quantification of in vivo 1H spectra. *Magn. Reson. Med.* 37, 651–657. doi:
 10.1002/mrm.1910370504.
- McDonald, O. G., Li, X., Saunders, T., Tryggvadottir, R., Mentch, S. J., Warmoes, M. O., et al.
 (2017). Epigenomic reprogramming during pancreatic cancer progression links anabolic
 glucose metabolism to distant metastasis. *Nat. Genet.* 49, 367–376. doi: 10.1038/ng.3753.
- 785 McGuire, L. C. (2006). Alcoholic ketoacidosis. *Emerg. Med. J.* 23, 417–420. doi:
 10.1136/emj.2004.017590.
- Moran, R. A., García-Rayado, G., de la Iglesia-García, D., Martínez-Moneo, E., Fort-Martorell, E.,
 Lauret-Braña, E., et al. (2018). Influence of age, body mass index and comorbidity on major
 outcomes in acute pancreatitis, a prospective nation-wide multicentre study. *United Eur. Gastroenterol. J.* 6, 1508–1518. doi: 10.1177/2050640618798155.
- Murphy, A. J., and Woollard, K. J. (2010). High-density lipoprotein: A potent inhibitor of
 inflammation. *Clin. Exp. Pharmacol. Physiol.* 37, 710–718. doi: 10.1111/j.14401681.2009.05338.x.
- Nadhem, O., and Salh, O. (2017). Acute Pancreatitis: An Atypical Presentation. Case Rep.
 Gastroenterol. 11, 359–363. doi: 10.1159/000475920.

Nalisa, M., Nweke, E. E., Smith, M. D., Omoshoro-Jones, J., Devar, J. W., Metzger, R., et al.
(2021). Chemokine receptor 8 expression may be linked to disease severity and elevated interleukin 6 secretion in acute pancreatitis. *World J. Gastrointest. Pathophysiol.* 12, 115– 133. doi: 10.4291/wjgp.v12.i6.115.

- National Health Laboratory Services 2019/20 Annual Report; National Health Amendment Bill:
 rejection | PMG (n.d.). Available at: https://pmg.org.za/committee-meeting/32510/
 [Accessed October 8, 2023].
- Nesvaderani, M., Eslick, G. D., Vagg, D., Faraj, S., and Cox, M. R. (2015). Epidemiology, aetiology
 and outcomes of acute pancreatitis: A retrospective cohort study. *Int. J. Surg.* 23, 68–74.
 doi: 10.1016/j.ijsu.2015.07.701.
- Niknam, R., Moradi, J., Jahanshahi, K. A., Mahmoudi, L., and Ejtehadi, F. (2020). Association
 Between Metabolic Syndrome and Its Components with Severity of Acute Pancreatitis.
 Diabetes Metab. Syndr. Obes. 13, 1289–1296. doi: 10.2147/DMSO.S249128.
- Ocskay, K., Vinkó, Z., Németh, D., Szabó, L., Bajor, J., Gódi, S., et al. (2021). Hypoalbuminemia
 affects one third of acute pancreatitis patients and is independently associated with severity
 and mortality. *Sci. Rep.* 11, 24158. doi: 10.1038/s41598-021-03449-8.
- Otvos, J. D., Shalaurova, I., Wolak-Dinsmore, J., Connelly, M. A., Mackey, R. H., Stein, J. H., et al.
 (2015). GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic
 Inflammation. *Clin. Chem.* 61, 714–723. doi: 10.1373/clinchem.2014.232918.
- Phatlhane, D. V., and Zemlin, A. E. (2016). Severe hypercholesterolemia mediated by lipoprotein X
 in a patient with cholestasis. *Ann. Hepatol.* 14, 924–928.

- 817 Quinlan, J. D. (2014). Acute Pancreatitis. Am. Fam. Physician 90, 632–639.
- Rakonczay, Z., Hegyi, P., Takacs, T., McCarroll, J., and Saluja, A. K. (2008). The role of NF[kappa]B activation in the pathogenesis of acute pancreatitis. *Gut* 57, 259. doi:
 10.1136/gut.2007.124115.
- Reynolds, A. P., Richards, G., de la Iglesia, B., and Rayward-Smith, V. J. (2006). Clustering Rules:
 A Comparison of Partitioning and Hierarchical Clustering Algorithms. *J. Math. Model. Algorithms* 5, 475–504. doi: 10.1007/s10852-005-9022-1.
- Rousseeuw, P. J. (1987). Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. *J. Comput. Appl. Math.* 20, 53–65. doi: 10.1016/0377-0427(87)90125-7.
- Sakai, A., Nishiumi, S., Shiomi, Y., Kobayashi, T., Izumi, Y., Kutsumi, H., et al. (2012).
 Metabolomic analysis to discover candidate therapeutic agents against acute pancreatitis. *Arch. Biochem. Biophys.* 522, 107–120. doi: 10.1016/j.abb.2012.03.025.
- Sandstrom, P., Trulsson, L., Gasslander, T., Sundqvist, T., von Dobeln, U., and Svanvik, J. (2008).
 Serum amino acid profile in patients with acute pancreatitis. *Amino Acids* 35, 225–231. doi: 10.1007/s00726-007-0557-5.
- Serkova, N., Florian Fuller, T., Klawitter, J., Freise, C. E., and Niemann, C. U. (2005). 1H-NMR–
 based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney
 transplants. *Kidney Int.* 67, 1142–1151. doi: 10.1111/j.1523-1755.2005.00181.x.
- Shah, I., Yakah, W., Ahmed, A., Freedman, S. D., Jiang, Z. G., and Sheth, S. G. (2023). GlycA:
 Evaluation of a New Biomarker of Acute Pancreatitis. *Biomolecules* 13, 1530. doi:
 10.3390/biom13101530.
- Siddiqui, M. A., Pandey, S., Azim, A., Sinha, N., and Siddiqui, M. H. (2020). Metabolomics: An
 emerging potential approach to decipher critical illnesses. *Biophys. Chem.* 267, 106462.
 doi: 10.1016/j.bpc.2020.106462.
- Silva, R. A., Pereira, T. C. S., Souza, A. R., and Ribeiro, P. R. (2020). 1H NMR-based metabolite
 profiling for biomarker identification. *Clin. Chim. Acta* 502, 269–279. doi:
 10.1016/j.cca.2019.11.015.
- Silva-Vaz, P., Abrantes, A. M., Morgado-Nunes, S., Castelo-Branco, M., Gouveia, A., Botelho, M.
 F., et al. (2020). Evaluation of Prognostic Factors of Severity in Acute Biliary Pancreatitis. *Int. J. Mol. Sci.* 21, 4300. doi: 10.3390/ijms21124300.
- Singh, A., Chen, M., Li, T., Yang, X.-L., Li, J.-Z., and Gong, J.-P. (2012). Parenteral Nutrition
 Combined with Enteral Nutrition for Severe Acute Pancreatitis. *ISRN Gastroenterol.* 2012, 1–7. doi: 10.5402/2012/791383.
- Soeters, P. B., Wolfe, R. R., and Shenkin, A. (2019). Hypoalbuminemia: Pathogenesis and Clinical
 Significance. J. Parenter. Enter. Nutr. 43, 181–193. doi: 10.1002/jpen.1451.
- Szatmary, P., Grammatikopoulos, T., Cai, W., Huang, W., Mukherjee, R., Halloran, C., et al.
 (2022). Acute Pancreatitis: Diagnosis and Treatment. *Drugs* 82, 1251–1276. doi:
 10.1007/s40265-022-01766-4.
- Szymańska, E., Saccenti, E., Smilde, A. K., and Westerhuis, J. A. (2012). Double-check: validation
 of diagnostic statistics for PLS-DA models in metabolomics studies. *Metabolomics* 8, 3–16.
 doi: 10.1007/s11306-011-0330-3.
- Thiyagarajan, U. M., and Amirthavarshini Ponnuswamy, R. T. (2020). Predictivity of Biochemical
 Markers on Aetiology and Length of Hospitalisation in Acute Pancreatitis.

- Thomson, J.-E., Brand, M., and Fonteh, P. (2018). The immune imbalance in the second hit of
 pancreatitis is independent of IL-17A. *Pancreatology* 18, 246–252. doi:
 10.1016/j.pan.2018.01.007.
- Thomson, J.-E., Nweke, E. E., Brand, M., Nel, M., Candy, G. P., and Fonteh, P. N. (2019).
 Transient expression of Interleukin-21 in the second hit of acute pancreatitis may potentiate
 immune paresis in severe acute pancreatitis. doi: 10.1097/MPA.00000000001207.
- Treacy, J., Williams, A., Bais, R., Willson, K., Worthley, C., Reece, J., et al. (2001). Evaluation of
 amylase and lipase in the diagnosis of acute pancreatitis. *ANZ J. Surg.* 71, 577–582. doi:
 10.1046/j.1445-2197.2001.02220.x.
- Valverde-López, F., Matas-Cobos, A. M., Alegría-Motte, C., Jiménez-Rosales, R., Úbeda-Muñoz,
 M., and Redondo-Cerezo, E. (2017). BISAP, RANSON, lactate and others biomarkers in
 prediction of severe acute pancreatitis in a European cohort. *J. Gastroenterol. Hepatol.* 32,
 1649–1656. doi: 10.1111/jgh.13763.
- Villaseñor, A., Kinross, J. M., Li, J. V., Penney, N., Barton, R. H., Nicholson, J. K., et al. (2014). 1H
 NMR Global Metabolic Phenotyping of Acute Pancreatitis in the Emergency Unit. *J. Proteome Res.* 13, 5362–5375. doi: 10.1021/pr500161w.
- Xiao, H., Huang, J., Zhang, X., Ahmed, R., Xie, Q., Li, B., et al. (2017). Identification of potential
 diagnostic biomarkers of acute pancreatitis by serum metabolomic profiles. *Pancreatology* 17, 543–549. doi: 10.1016/j.pan.2017.04.015.
- Xiao, W., Liu, W., Yin, L., Li, Y., Lu, G., Liu, X., et al. (2020). Serum hydroxybutyrate
 dehydrogenase as an early predictive marker of the severity of acute pancreatitis: a
 retrospective study. *BMC Gastroenterol.* 20, 393. doi: 10.1186/s12876-020-01521-7.
- Xu, H., Zhang, L., Kang, H., Zhang, J., Liu, J., and Liu, S. (2016). Serum Metabonomics of Mild Acute Pancreatitis. *J. Clin. Lab. Anal.* 30, 990–998. doi: 10.1002/jcla.21969.
- Xu, J., Pan, T., Qi, X., Tan, R., Wang, X., Liu, Z., et al. (2020). Increased mortality of acute
 respiratory distress syndrome was associated with high levels of plasma phenylalanine.
 Respir. Res. 21, 99. doi: 10.1186/s12931-020-01364-6.
- Yadav, D., and Lowenfels, A. B. (2013). The Epidemiology of Pancreatitis and Pancreatic Cancer.
 Gastroenterology 144, 1252–1261. doi: 10.1053/j.gastro.2013.01.068.
- Yang, A. L. (2008). Epidemiology of Alcohol-Related Liver and Pancreatic Disease in the United
 States. Arch. Intern. Med. 168, 649. doi: 10.1001/archinte.168.6.649.
- Yang, A. L., and McNabb-Baltar, J. (2020). Hypertriglyceridemia and acute pancreatitis.
 Pancreatology 20, 795–800. doi: 10.1016/j.pan.2020.06.005.
- Yuksekdag, S., Yuksel, E., Topcu, A., Karaagac, N., Uzun, H., Kiziler, A. R., et al. (2019). Serum
 paraoxonase (a high-density lipoprotein-associated lipophilic antioxidant) activity in clinical
 follow-up of patients with acute pancreatitis, with particular emphasis on oxidative stress
 parameters and lipid profile: a prospective pilot trial. *Libyan J. Med.* 14, 1595955. doi:
 10.1080/19932820.2019.1595955.
- Zhang, Y., Guo, F., Li, S., Wang, F., Meng, Z., Zhao, J., et al. (2017). Decreased high density
 lipoprotein cholesterol is an independent predictor for persistent organ failure, pancreatic
 necrosis and mortality in acute pancreatitis. *Sci. Rep.* 7, 8064. doi: 10.1038/s41598-01706618-w.
- Zheng, L., Xue, J., Jaffee, E. M., and Habtezion, A. (2013). Role of Immune Cells and Immune Based Therapies in Pancreatitis and Pancreatic Ductal Adenocarcinoma. *Gastroenterology*

- 904 144, 1230–1240. doi: 10.1053/j.gastro.2012.12.042.
- 205 Zilio, M. B., Eyff, T. F., Azeredo-Da-Silva, A. L. F., Bersch, V. P., and Osvaldt, A. B. (2019). A
- systematic review and meta-analysis of the aetiology of acute pancreatitis. *HPB* 21, 259–
 267. doi: 10.1016/j.hpb.2018.08.003.

908